A Randomized, Double-Blind, Multi-Center, Parallel-Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD (Ethos)
A Randomized, Double-Blind, Multi-Center, Parallel-Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD (Ethos)
This is a randomized, double-blind, multi-center, parallel-group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations subjects with moderate to very severe COPD.
A randomized, double-blind, multi-center, parallel-group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations over a 52-week treatment period in subjects with moderate to very severe COPD.
Inclusion Criteria
Please refer to the study protocol for the complete inclusion criteria list.
Exclusion Criteria
Please refer to the study protocol for the complete inclusion criteria list.
CABA, C1056ABJ, Argentina
Capital Federal, C1122AAK, Argentina
Ciudad Autonoma de Buenos Aire, C1028AAP, Argentina
Ciudad Autonoma de Buenos Aire, C1120AAC, Argentina
Ciudad Autonomade Buenos Aires, 1426, Argentina
Ciudad Autónoma de Bs. As., 1426, Argentina
Ciudad Capital, 5500, Argentina
Ciudad de Buenos Aire, C1425BEN, Argentina
Grosshansdof, 22927, Germany
Osakasayama-shi, 589-8511, Japan
Sakaide-shi, 762-8550, Japan
Seto-shi, 489-8642, Japan
Shinagawa-ku, 142-8666, Japan
Yanagawa-shi, 832-0059, Japan
Greenlane East, 1051, New Zealand